咨询客服 咨询客服

Valvectomy versus replacement for the surgical treatment of infective tricuspid valve endocarditis: a systematic review and meta-analysis.

Abstract:
Background\nOptimal surgical treatment of infective tricuspid valve endocarditis in patients with intravenous drug use (IVDU) remains controversial. Tricuspid valvectomy has been proposed for infective tricuspid valve endocarditis in this patient population given the inherent social concerns. The aim of this systematic review and meta-analysis was to compare outcomes of valvectomy versus replacement for the surgical treatment of isolated infective tricuspid valve endocarditis.\n\n\nMethods\nAn electronic search was performed to identify all relevant studies published. After assessment for inclusion and exclusion criteria, 16 original studies were pooled for systematic review and meta-analysis.\n\n\nResults\nThere were a total of 752 patients with infective tricuspid valve endocarditis, of which 14% underwent valvectomy and 86% underwent replacement (mean follow-up 4.2 years, 95% CI, 1.9-6.4 years). The most common indications for surgical intervention were septic pulmonary embolism in the valvectomy group (74%, 95% CI, 28-95%) and persistent sepsis in the replacement group (62%, 95% CI, 31-86%). There were no differences in rates of stroke [valvectomy 4% (95% CI, 1-11%) vs. replacement 3% (95% CI, 1-16%), P=0.85] but there was increased likelihood of prolonged ventilation in those who underwent valvectomy [valvectomy 40% (95% CI, 30-51%) vs. replacement 26% (95% CI, 23-30%), P<0.01]. There were no differences in 30-day post-operative mortality [valvectomy 13% (95% CI, 5-30%) vs. replacement 7% (95% CI, 5-10%), P=0.21], post-operative right heart failure [valvectomy 27% (95% CI, 10-53%) vs. replacement 11% (95% CI, 5-25%), P=0.17] and recurrent endocarditis [valvectomy 7% (95% CI, 2-23%) vs. replacement 19% (95% CI, 12-28%), P=0.81]. Valvectomy had a higher rate of tricuspid valve reoperation [valvectomy 56% (95% CI, 15-90%) vs. initial replacement 14% (95% CI, 7-27%), P=0.06].\n\n\nConclusions\nTricuspid valvectomy is an acceptable initial therapy for infective tricuspid valve endocarditis in patients with IVDU, providing a bridge to identify those who will self-select as candidates for staged valve replacement.
Author Listing: Jessica G Y Luc;Jae-Hwan Choi;Karishma Kodia;Matthew P Weber;Dylan P Horan;Elizabeth J Maynes;Laura A Carlson;H Todd Massey;John W Entwistle;Rohinton J Morris;Vakhtang Tchantchaleishvili
Volume: 8 6
Pages: \n 610-620\n
DOI: 10.21037/acs.2019.11.06
Language: English
Journal: Annals of cardiothoracic surgery

Annals of Cardiothoracic Surgery

ANN CARDIOTHORAC SUR

影响因子:3.1
是否综述期刊:否
是否OA:否
是否预警:不在预警名单内
发行时间:-
ISSN:2225-319X
发刊频率:-
收录数据库:SCIE/Scopus收录
出版国家/地区:China
出版社:AME Publishing Company

期刊介绍

Information not localized

信息未本地化

年发文量 43
国人发稿量 1
国人发文占比 1.69%
自引率 3.2%
平均录取率 -
平均审稿周期 -
版面费 -
偏重研究方向 Medicine-Surgery
期刊官网 http://www.annalscts.com/
投稿链接 http://www.annalscts.com/author/submitYourManuscript

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
81.40% 99.32% 0.00% 0.00%

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

时间 预警情况
2025年03月发布的2025版 不在预警名单中
2024年02月发布的2024版 不在预警名单中
2023年01月发布的2023版 不在预警名单中
2021年12月发布的2021版 不在预警名单中
2020年12月发布的2020版 不在预警名单中

JCR分区 WOS分区等级:Q1区

版本 按学科 分区
WOS期刊SCI分区
(2021-2022年最新版)
SURGERY Q2
CARDIAC & CARDIOVASCULAR SYSTEMS Q1

中科院分区

版本 大类学科 小类学科 Top期刊 综述期刊
医学
2区
SURGERY
外科
2区
CARDIAC & CARDIOVASCULAR SYSTEMS
心脏和心血管系统
3区
2021年12月
基础版
医学
3区
SURGERY
外科
3区
CARDIAC & CARDIOVASCULAR SYSTEMS
心脏和心血管系统
3区
2021年12月
升级版
医学
2区
SURGERY
外科
2区
CARDIAC & CARDIOVASCULAR SYSTEMS
心脏和心血管系统
3区
2020年12月
旧的升级版
医学
2区
SURGERY
外科
2区
CARDIAC & CARDIOVASCULAR SYSTEMS
心脏和心血管系统
3区
2022年12月
最新升级版
医学
2区
SURGERY
外科
2区
CARDIAC & CARDIOVASCULAR SYSTEMS
心脏和心血管系统
3区